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Destruction of cancer cells by therapeutic anti-
bodies occurs, at least in part, through antibody-
dependent cellular cytotoxicity (ADCC), and this
can be mediated by various Fc-receptor-expressing
immune cells, including neutrophils. However, the
mechanism(s) by which neutrophils kill antibody-
opsonized cancer cells has not been established.
Here, we demonstrate that neutrophils can exert a
mode of destruction of cancer cells, which involves
antibody-mediated trogocytosis by neutrophils. Inti-
mately associated with this is an active mechanical
disruption of the cancer cell plasma membrane,
leading to a lytic (i.e., necrotic) type of cancer cell
death. Furthermore, this mode of destruction of
antibody-opsonized cancer cells by neutrophils is
potentiated by CD47-SIRPa checkpoint blockade.
Collectively, these findings show that neutrophil
ADCC toward cancer cells occurs by a mechanism
of cytotoxicity called trogoptosis, which can be
further improved by targeting CD47-SIRPa interac-
tions.3946 Cell Reports 23, 3946–3959, June 26, 2018 Crown Copyright ª
This is an open access article under the CC BY-NC-ND license (http://INTRODUCTION
Therapeutic monoclonal antibodies directed against tumor anti-
gens expressed on cancer cells have been a valuable alternative
or addition to conventional cancer treatment modalities such as
chemotherapy for >25 years (Glennie and van de Winkel, 2003;
Oldham and Dillman, 2008). In general, cancer therapeutic anti-
bodies act by a combination of direct and indirect immune-medi-
ated effects, including complement-dependent cytotoxicity and
antibody-dependent cellular cytotoxicity (ADCC). ADCC can be
mediated through the activation of different Fc receptors and
by different Fc receptor-expressing cells, such as natural killer
(NK) cells, macrophages, and neutrophils (Albanesi et al.,
2013; Bryceson and Long, 2008; Musolino et al., 2008; Nimmer-
jahn and Ravetch, 2008; Strome et al., 2007). Whereas the
different Fcg receptors involved in inducing ADCC, FcgRI,
FcgRII, and FcgRIII have different binding affinities for immuno-
globulin G (IgG) and different cell-specific expression, for neutro-
phils we have found FcgIIa to be the predominant Fc receptor
inducing ADCC in breast cancer cells (Treffers et al., 2018).
Furthermore, it is known that NK cells and macrophages primar-
ily cause ADCC by granule-dependent apoptotic (Bryceson
and Long, 2008) and phagocytic (Chao et al., 2010a; G€ul et al.,
2014; Montalvao et al., 2013) mechanisms, respectively. How-
ever, the cytotoxic mechanism(s) by which neutrophils destroy2018
creativecommons.org/licenses/by-nc-nd/4.0/).
antibody-opsonized cancer cells have remained essentially un-
known (Albanesi et al., 2013; van Egmond and Bakema, 2013).
Neutrophils frequently are encountered in human cancers (Eru-
slanov et al., 2014), and there is compelling evidence that they
contribute substantially to antibody-mediated tumor cell
destruction in vivo (Albanesi et al., 2013; Hernandez-Ilizaliturri
et al., 2003; Ring et al., 2017; Siders et al., 2010; Zhu et al.,
2015). Furthermore, insight into the mechanism of neutrophil
ADCC may offer opportunities for further improvement in the ef-
ficacy of antibody therapy in cancer.
In spite of the beneficial effects documented for various ther-
apeutic antibodies against different types of cancer, antibodies
alone are not curative and therefore there is a pertinent need to
improve their efficacy. By analogy to T cell immunity against can-
cer, which can be promoted by the inhibitors of immune check-
points such as programmed cell death-1-programmed cell death
ligand-1 (PD1-PDL1) interactions (Topalian et al., 2015), we and
others have demonstrated that targeting interactions between
the ‘‘don’t-eat-me’’ signal CD47 on cancer cells and the inhibi-
tory immunoreceptor signal regulatory protein a (SIRPa) ex-
pressed on myeloid cells, including macrophages and neutro-
phils, potentiates antibody-dependent cancer cell destruction
by those cells both in vitro and in vivo (Barclay and van den
Berg, 2014; Chao et al., 2010a; Soto-Pantoja et al., 2012; Weis-
kopf et al., 2013; Zhao et al., 2011, 2012a, 2012b). Furthermore,
CD47 frequently is overexpressed on cancer cells, and the clin-
ical efficacy of antibody therapy against both hematological and
solid cancers is inversely related to the expression levels of
CD47 (Chao et al., 2010a; Majeti et al., 2009; Zhao et al.,
2011). SIRPa is known to function as a typical inhibitory receptor
that upon CD47 binding recruits and activates the protein tyro-
sine phosphatases Src homology region 2 domain-containing
phosphatase-1 and -2 (SHP-1 and SHP-2) (Barclay and van
den Berg, 2014), and blocking CD47-SIRPa interactions pro-
motes the phagocytosis of opsonized tumor cells by macro-
phages (Chao et al., 2010a; Jaiswal et al., 2009; Majeti et al.,
2009). Nevertheless, the mechanism(s) by which blockade of
the CD47-SIRPa checkpoint enhances antibody-dependent
cancer cell killing by neutrophils is not known, and this clearly re-
quires insight into the cytotoxic mechanism by which neutrophils
destroy antibody-opsonized cancer cells.
Our findings, presented here, suggest that neutrophils can kill
antibody-opsonized cancer cells by a process that involves the
active mechanic destruction of the target cell plasma mem-
brane, leading to a form of immune cell-mediated necrotic
type of cell death. This type of cytotoxicity appears intimately
linked to a process of antibody-dependent trogocytosis, in
which neutrophils endocytose, in both a cancer therapeutic
antibody- and a cell-cell contact-dependent fashion, cyto-
plasmic fragments of the target cells. Trogocytosis was identi-
fied originally by Tabiasco et al. (2002) as an active mechanism
of plasmamembrane transfer among host (immune) cells. While
the actual function(s) of the process have remained largely
elusive (Joly and Hudrisier, 2003), evidence for the possible
relevance of trogocytosis via immune cells has accumulated
more recently. Notably, trogocytosis has been implicated as
acting as a tolerogenic mechanism that mediates shaving of
the target antigen CD20 from tumor cells in the context of ritux-imab treatment of B cell malignancies, thereby preventing
further susceptibility of the cancer cells toward anti-CD20
antibody-mediated destruction (Taylor and Lindorfer, 2015;
Valgardsdottir et al., 2017). Trogocytosis by the parasite
Entamoeba histolytica also has been proposed to inflict
necrotic tissue damage to host cells during infection, which
uses a trogocytosis-like process to inflict necrotic tissue dam-
age to the host (Ralston et al., 2014). In line with the latter, there
is evidence that trogocytosis occurs during macrophage-medi-
ated ADCC toward trastuzumab-opsonized breast cancer cells
(Velmurugan et al., 2016), but a direct causal relation between
immune cell-mediated trogocytosis and tumor cell killing was
not demonstrated in these studies.
Here, we report direct evidence that neutrophil ADCC involves
a trogocytosis-related necrotic process of tumor cell death,
referred to as trogoptosis. In particular, we show that neutrophil
trogocytosis, which occurs both in vitro and in vivo and critically
involves CD11b/CD18-dependent conjugate formation, coin-
cides in a spatiotemporal fashion with the trogoptotic (i.e., lytic)
death of antibody-opsonized solid cancer cells. Finally, inhibition
of neutrophil trogocytosis prevents target cell trogoptosis,
whereas promotion of trogocytosis by interference of CD47-
SIRPa interactions enhances killing.
RESULTS
Killing of Antibody-Opsonized Cancer Cells by
Neutrophils Requires CD11b/CD18 Integrin-Dependent
Conjugate Formation
To provide more insight into the mechanism of neutrophil ADCC
toward cancer cells, we investigated whether neutrophil ADCC
required direct cell-cell interactions. Indeed, intimate effector-
target interactions, reminiscent of killer synapses that are well
established to be required for cytotoxicity by NK cells and cyto-
toxic T lymphocytes (CTLs) (Dustin and Long, 2010) but also
have been reported for neutrophils (van Spriel et al., 2001,
2003), were demonstrated during neutrophil ADCC using trastu-
zumab-opsonized breast cancer cells (Figure 1A). The extent to
which these conjugates occur was quantified by ImageStream
flow cytometry (Figure 1B). Interference with CD47-SIRPa inter-
actions by, for example, knock down of CD47 in breast cancer
target cells, which was shown to potentiate neutrophil ADCC
(Zhao et al., 2011), enhanced conjugate formation (Figure 1C),
but the overall appearance of the resultant conjugate was not
notably altered by CD47 knockdown (data not shown). Conju-
gate formation by neutrophils required Fcg receptor (FcgR)
occupation by antibody-opsonized tumor cells and CD11b/
CD18 integrin-mediated adhesion, as shown by antibody-block-
ing experiments (Figure 1C). Prevention of conjugate formation
by blocking Fcg receptor (Figure S1A) and, in particular, FcgRIIa
(Treffers et al., 2018; Figure S1B) or CD11b/CD18 integrins (Fig-
ure 1D) but not that of other CD18 (b2)- and CD29 (b1)-integrins
(Figures S1C and S1D), essentially abolished ADCC. These find-
ingswere consistent with previous observations (van Spriel et al.,
2001) and corroborated by using neutrophils from a rare patient
with leukocyte adhesion deficiency (LAD)-1 syndrome (van de
Vijver et al., 2012), which lacks CD18 integrins because of a
mutation in the ITGB2 gene encoding this protein (FiguresCell Reports 23, 3946–3959, June 26, 2018 3947
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Figure 1. Neutrophil ADCC toward Cancer
Cells Requires CD18 Integrin-Mediated
Conjugate Formation
(A) Conjugate formation between a human neutro-
phil (N) and trastuzumab (Tmab)-opsonized SKBR3
breast cancer cells (T) as visualized by confocal
fluorescence microscopy after staining of F-actin
with phalloidin-rhodamine and nuclei with Hoechst.
Note the accumulation of F-actin at the interface
between the cells. Scale bar represents 10 mm.
(B) ImageStream-X flow cytometric quantification
of conjugate formation between calcein-AM-
labeled (green fluorescence) neutrophils and
Tmab-opsonized cell tracker red-labeled (red
fluorescence) SKBR3 cells analyzed after 45 min
coincubation. A typical example of a microscopic
image of a neutrophil-Tmab-cancer cell conjugate
generated by the ImageStream-X flow cytometer
also is shown.
(C) CD11b/CD18 and Fcg receptor dependence
of neutrophil conjugate formation with Tmab-
opsonized SKBR3 cells, as shown by inhibition
with anti-CD11b-blocking; anti-CD18-blocking
antibodies; or a mixture of anti-CD64-, anti-CD32-
, and anti-CD16-blocking antibodies (anti-FcRs).
Data are average values ± SEMs (n = 4 biological
replicates, 2 independent experiments).
(D) Neutrophil ADCC requires conjugate formation
as demonstrated by blocking with anti-CD11b,
anti-CD18 antibodies, or both. Data are average
values ± SEMs (n = 3 biological replicates, 2 in-
dependent experiments). Statistical significance
was tested with ANOVA followed by Sidak post-
hoc test. *p % 0.05; **p % 0.01.S1E–S1G). Thus, neutrophil cytotoxic conjugate formation is a
strictly CD11b/CD18-dependent process, and it forms a prereq-
uisite for ADCC toward cancer cells, both in the presence and
absence of CD47-SIRPa interactions.
Antibody-Dependent Destruction of Cancer Cells by
Neutrophils Involves a Non-apoptotic Mechanism
Independent of Granule Exocytosis and the Phagocyte
NADPH Oxidase
Because neutrophils lack the capacity to phagocytose cancer
cells (Valgardsdottir et al., 2017), we evaluated whether human
neutrophil ADCC was mediated by an extracellular mechanism
dependent on granule exocytosis. For this purpose, we used
neutrophils from rare familial hemophagocytic lymphohistiocyto-
sis (FHL)-5 patients, which have mutations in the STXBP2 gene
encoding the munc18-2 protein (Figure S1E) (de Saint Basile
et al., 2010; Meeths et al., 2010). Both neutrophils and NK cells
from such patients have defects in granule release (Meeths
et al., 2010; Zhao et al., 2013). Although evidence for granule
exocytosis during ADCC was obtained by healthy control neu-
trophils, as exemplified by the release of myeloperoxidase
(MPO) (Figure S2A), neutrophils of patients with FHL-5 showed
completely normal killing of Her2/Neu+ breast cancer cells in
the presence of the therapeutic anti-Her2/Neu monoclonal anti-
body trastuzumab (Tmab) (Figure S2B). In contrast, as expected,
NK cell-mediated ADCC, which involves the release of gran-
zymes and perforin from exocytosed granules that cause target3948 Cell Reports 23, 3946–3959, June 26, 2018cell apoptosis (Bryceson and Long, 2008; Dustin and Long,
2010), was profoundly impaired (Figure S2C). These findings
excluded a neutrophil extracellular granule-dependent mecha-
nism of cytotoxicity during ADCC. Furthermore, the other major
antimicrobial effector mechanism of neutrophils (Reeves et al.,
2002; Segal, 2005), which involves the formation of reactive
oxygen species by the phagocyte nicotinamide adenine dinucle-
otide phosphate (NADPH) oxidase, was also excluded by testing
neutrophils from patients with chronic granulomatous disease
(CGD) (Figures S1E, S2D, and S2E) having mutations in compo-
nents of the NADPHoxidase, causing a complete lack of produc-
tion of reactive oxygen species (Roos et al., 2003; Segal, 2005).
Finally, the possible redundancy between both effector path-
ways could be excluded as well because inhibition of NADPH
oxidase by diphenyleneiodonium (DPI) in neutrophils from pa-
tients with FHL-5 did not significantly affect their ADCC capacity
(Figure S2F).
Neutrophil and NK cell-mediated ADCC appeared to involve
different types of cell death, because neutrophil-mediated
ADCC was not influenced by the use of the caspase inhibitor
N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone
(Z-VAD-FMK) (Figure S2G). In addition, neutrophils did not
induce the typical signs of apoptotic cancer cell death, as is
seen with NK cells as effector cells (Figure S2H). Rather, neutro-
phil-mediated ADCC seemed to involve a non-apoptotic type of
cell death associated with cell lysis and loss of cytoplasmic
material.
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Figure 2. Neutrophils Cause Antibody-
Opsonized Cancer Cell Destruction by Tro-
goptosis
(A) Antibody-dependent trogocytic uptake of
cancer cell membrane material by human neu-
trophils. Neutrophils were incubated with DiO-
labeled SKBR3 breast cancer cells (T) at an ef-
fector:target cell (E:T) ratio of 5:1 in the presence
of Tmab, and acquisition of labeled cancer
membrane material by neutrophils (white arrows)
was visualized by confocal fluorescent micro-
scopy. Scale bar represents 10 mm.
(B) Ultrastructural localization of trogocytic in-
vaginations (black arrows) at the neutrophil (N)
conjugate with a Tmab-opsonized SKBR3 cell (T).
(C) Trogocytic uptake visualized by electron mi-
croscopy at the interface between Tmab-opson-
ized biotin-labeled SKBR3 cells and neutrophils
(N). Note the initial trogocytic invaginations (blue
and brown insets) and endosome-like vesicles
(green inset) containing biotin-labeled tumor ma-
terial (T).
(D and E) SEM images of the trogocytic process of
antibody-opsonized SKBR3 CD47KD cells (T) by
neutrophils (N). White arrows show intact cell-cell
contacts between neutrophils and SKBR3 cells
(D); red arrows show disruption of the target cell
membrane (D and E). Images were made after 45-
min incubation of neutrophils with antibody-
opsonized tumor cells.Neutrophils Kill Antibody-Opsonized Cancer Cells by
Trogoptosis
We further explored the possible nature of the cytotoxic effector
mechanism during neutrophil ADCC by live cell imaging. This re-
vealed the dynamic nature of neutrophils, which is characterized
by active migratory behavior, and the transient formation of con-
jugates with the cancer cells in the presence of Tmab (data not
shown). When the cancer cell membranes were labeled with a
hydrophobic fluorescent dye, such as 3,30-dioctadecyloxacar-
bocyanine perchlorate (DiO), we observed that these contacts
actually led to the acquisition of fragments of target cell mem-Cell Rebrane by the neutrophils (Videos S1
and S2; Figure 2A) in a way that was
reminiscent of trogocytosis. Our subse-
quent ultrastructural analysis of conju-
gates of biotin-labeled breast cancer
cells revealed trogocytic invaginations
and sometimes cup-like structures con-
taining target cell plasma membrane at
the neutrophil surface, as well as endo-
some-like vesicles within the cytosol
(Figures 2B and 2C). Simultaneous label-
ing for granule markers such as MPO or
lactoferrin (LF), derived from azurophilic
and specific neutrophil granules, respec-
tively (Borregaard et al., 2007), identified
tumor plasma membrane material within
double-labeled phagosomes; this is
indicative of endocytic ingestion, phago-some-azurophilic and -specific granule fusion, and phagolyso-
somal degradation (Figures S3A and S3B). Using scanning elec-
tron microscopy (EM), neutrophils were shown to form intimate
interactions with the antibody-opsonized tumor cells (Figures
2D and 2E). A significant number of these contacts showed a dis-
rupted appearance, which is indicative of active disruption of the
target cell plasma membrane by the neutrophils.
To investigate whether neutrophil trogocytosis has a direct
causal relation to target cell death, we monitored cancer cell
plasma membrane destruction simultaneously by using target
cells loaded with the cytosolic dye calcein (Videos S2 and S3;ports 23, 3946–3959, June 26, 2018 3949
Figure 3A). Both live cell imaging and flow cytometry analysis re-
vealed that at least a proportion of the neutrophil interactions
that were associated with trogocytosis led to a significant reduc-
tion in cancer cell cytoplasmic labeling (Figures 3B and 3C).
Furthermore, neutrophil trogocytosis, as quantified by flow cy-
tometry, was a rapid process that could be detected within
15 min (Figure 3D), and its kinetics coincided well with cytotoxic
trogoptosis, as monitored by the 51Cr release assay (Figure 3E).
This time course of neutrophil killing during ADCC, which rapidly
peaked within 2–4 hr, also was different from that of NK cell
ADCC (Figure S3C), which requires apoptosis induction. It
should be emphasized that it is not so much the antibody-
induced trogocytosis that appears specific to neutrophils, but
rather their capacity to induce the killing of opsonized target cells
by a trogocytosis-related process. For instance, NK cells also
are capable of trogocytosis in an antibody-dependent fashion.
However, whereas the cytotoxicity of NK cells from patients
with FHL-5 is essentially defective (Figure S2C), their trogocyto-
sis appears to be unaffected by FHL-5 mutation (Figure S3D).
Together, these data further emphasize the fundamentally
different nature of the cytotoxicity evoked by the two types of im-
mune effector cells.
Using a plasma membrane-impermeable LIVE/DEAD indica-
tor, either present in the extracellular medium during the exper-
iment (Video S4; Figures 4A–4F) or used at the end of the assay
period (Figures 4G and 4H), revealed that neutrophil trogocytic
interactions were causing a lytic (i.e., necrotic) form of cell death
of the antibody-opsonized cancer cells, which we have pro-
posed to call trogoptosis. Like conjugate formation, neutrophil
trogocytosis and the associated trogoptosis were entirely anti-
body dependent (Figure 4H). Furthermore, as expected, neutro-
phil trogocytosis required conjugate formation, because it could
be prevented by blocking CD11b/CD18 (Figure S3E). Neutrophil
trogoptosis led to a significant and substantial loss of the plasma
cell membrane of antibody-opsonized cancer cells, as deter-
mined by the reduction in Her2/neu expression (Figures 4I and
4J). Finally, quantification of the amount of 1,10-Dioctadecyl-
3,3,30,30-Tetramethylindodicarbocyanine, 4-Chlorobenzenesul-
fonate Salt (DiD) staining shows that cancer cells that died
from neutrophil interactions had lost more plasma cell mem-
brane compared to cells that were still alive, further strength-
ening our conclusion that neutrophil trogocytosis is related caus-
ally to cell death of antibody-opsonized cancer cells (Figures 4K
and 4L).
Our findings have consistently demonstrated that interference
with CD47-SIRPa interactions, either by knocking down CD47
on cancer cells (Zhao et al., 2011 and data herein) or adding
antagonistic antibodies against CD47 or SIRPa that had been
shown to promote ADCC (Zhao et al., 2011) (Figure S4A), poten-
tiated the effects of cancer therapeutic antibodies to trigger tro-
gocytosis and killing. Neutrophil trogocytosis and the related
cytotoxicity also were observed with other solid cancer target
cell and therapeutic antibody combinations, as shown for A431
carcinoma cells. A431 carcinoma cells endogenously express
the epidermal growth factor receptor (EGFR) in conjunction
with the anti-EGFR antibody therapeutic cetuximab (Cmab) or
by using A431 cells ectopically expressing the Her2 surface an-
tigen in combination with Tmab (Figures S4C–S4F).3950 Cell Reports 23, 3946–3959, June 26, 2018Trogocytosis and Trogoptosis by Neutrophils In Vivo
We investigated the possibility of the in vivo occurrence of
neutrophil trogoptosis toward antibody-opsonized cancer cells
in the Kupffer cell-depleted mouse liver using a B16F10 mela-
noma model (G€ul et al., 2014). When CD47-SIRPa interactions
were disturbed by SSL6, a Staphylococcus aureus-derived pro-
tein that binds to CD47 and is known to block CD47 binding to
SIRPa (Fevre et al., 2014), the metastatic load of the tumor cells
in the liver was strongly inhibited, demonstrating that interfer-
ence of CD47-SIRPa interactions potentiates antibody-depen-
dent tumor cell clearance by the remaining myeloid cells in this
model (Figure 5A). This is consistent with enhanced mouse
neutrophil-mediated destruction of the antibody-opsonized can-
cer cells observed in vitro (Figures S5A and S5B). Direct evi-
dence for the prominent role of neutrophils as effector cells in
this particular in vivomodel was further obtained by the depletion
of neutrophils by injection of the anti-Ly6G antibody (clone 1A8),
which resulted in a significantly enhanced tumor load (Figure 5D).
Using intravital microscopy, a significant amount of migratory
neutrophils carrying tumor membrane material were seen in
TA99-treated mice compared to isotype control treated animals
(Figures 5B and 5C; Video S5). Furthermore, neutrophils could
be observed that were actively involved in trogocytosing pieces
of membrane from the antibody-opsonized tumor cells (Fig-
ure 5E; Video S6). Following propidium iodide injection, neutro-
phil-mediated trogoptotic cell death also could be demonstrated
under these conditions (Figure 5F; Video S7).
Finally, immunohistochemistry or flow cytometry evaluation
of the biopsies from patients with Her2-positive breast cancer
that was responsive to neoadjuvant Tmab therapy revealed
numerous neutrophils that had infiltrated the cancer tissue.
Many of these neutrophils directly interacted with the breast can-
cer tissue and some had apparently taken up the Her2-contain-
ing cancer cell membrane, which is consistent with neutrophil
trogocytosis of antibody-opsonized cancer cells in such patients
(Figures S5C and 6A). Moreover, isolation of neutrophils from
breast cancer tissue after Tmab treatment confirmed the intra-
cellular staining for Her2 in neutrophils (Figures S5D and 6B).
Collectively, the findings described above show that it is reason-
able to assume that neutrophil trogocytosis and trogoptosis
occur in vivo toward antibody-opsonized cancer cells in both
mice and humans.
Intracellular Signaling in Neutrophils during Trogoptosis
To provide evidence that the induction of cancer cell trogoptosis
by neutrophils is an active process that requires signaling down-
stream of Fcg receptors in neutrophils, we tested the effect of
pharmacological inhibition of the tyrosine kinase Syk, which is
known to play a pivotal role upstream in the Fcg receptor
signaling cascade (Mo´csai et al., 2010). Syk inhibition essentially
abolished all aspects of the process, including conjugate forma-
tion, trogocytosis, and cytotoxicity (Figures 7A–7C), demon-
strating that all of these responses require Fcg receptor signaling
in neutrophils. Further insight into the downstream signaling
pathway(s) instrumental in neutrophil trogocytosis was obtained
by performing an unbiased screen of 1,280 pharmacologically
active compounds using our flow cytometric trogocytosis assay
(Table S1). Among the selected compounds, we found inhibition
Figure 3. Trogocytosis of Antibody-Opsonized Cancer Cells by Neutrophils Leads to a Reduction in Cancer Cell Cytoplasmic Labeling and
Coincides with Cytotoxicity
(A) Stills of the trogoptotic disruption (arrow) of a calcein-AM-labeled tumor cell (T) as revealed by live cell confocal video microscopy. Time (min) is indicated
(upper left corner) from the start of the recording 15 min after the initiation of the experiment, with the 3 frames covering a total period of 36 s extracted from
Video S3. Scale bar represents 10 mm.
(B) Gating strategy for fluorescence-activated cell sorting (FACS)-based trogocytosis and ADCC assay. SKBR3 cells are gated on the genetic expression of lamin
B-GFP; neutrophils are negative for lamin B-GFP (left). SKBR3 cells lost the intracellular calcein red-orange label when opsonized with trastuzumab and incu-
bated with neutrophils for 4 hr, and this calcein red-orange loss is enhanced when CD47-SIRPa interactions are blocked by an anti-SIRPa antibody (right,
representative histograms).
(C) Loss of intracellular calcein red-orange in SKBR3 cells as a percentage of the control after the duration of the experiment (n = 6 biological replicates, 3 in-
dependent experiments).
(D and E) Kinetics of Tmab-mediated neutrophil trogocytosis quantified by flow cytometry (D) or cytotoxicity determined in parallel by 51Cr-release (E) with either
control SKBR3 cells or CD47KD SKBR3 cells. Note that the kinetics of both trogocytosis and cytotoxicity are similar and that both processes can be detected as
early as 15–30 min after coincubation of effector and target cells (n = 4 biological replicates, 2 independent experiments). Furthermore, trogocytosis, like killing, is
strictly antibody dependent, and interference with CD47-SIRPa interactions leads to enhanced trogocytosis and cytotoxicity. Statistical significance was tested
with multiple t test; *p% 0.05.
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Figure 4. Trogoptosis of Tumor Cells
Caused by Trogocytosis of Neutrophils dur-
ing ADCC
(A–F) (A) Still images of confocal live cell imaging
(taken from Video S4 at the indicated times [min]
after recording, which was started 5 min after
initiation of the experiment) of human neutrophils
incubated with both DiO-labeled (green fluores-
cence) and calcein-AM-labeled (red fluorescence)
SKBR3 CD47KD cells opsonized with trastuzu-
mab (E:T ratio = 5:1). The experiment was per-
formed in medium containing the DNA-binding
dye TO-PRO3 (blue fluorescence). Scale bar rep-
resents 10 mm. Note a neutrophil (B) trogocytosing
a fragment of tumor cell plasma membrane (ar-
row), directly followed (C, D, and E) by trogoptotic
lysis (arrow), leading to permeabilization and TO-
PRO3 staining of nuclear DNA (arrow) and further
cytoplasmic dismantling of the cancer cell (F). Also
note the yellow fluorescent dead cancer cell.
(G) Representative FACS histograms of LIVE/
DEAD-violet staining of SKBR3 cells, as gated for
as described in Figure 3B. Gates show the per-
centage of SKBR3 cells that became positive for
the LIVE/DEAD staining after incubation with
neutrophils and the indicated conditions for 4 hr.
Note that opsonizing SKBR3 cells with Tmab leads
to an increase in the amount of dead SKBR3 cells
and that this can be further enhanced after CD47-
SIRPa checkpoint inhibition.
(H) Percentage of dead SKBR3 cells after 4-hrin-
cubation with neutrophils, as determined by FACS
in combination with LIVE/DEAD-violet staining.
Results shown are averages ± SEM from 4 inde-
pendent experiments with neutrophils from 7 in-
dividual donors. Statistical significancewas tested
with ANOVA; **p% 0.01.
(I) RepresentativehistogramsofHer2/neustainingon
SKBR3 cells after 4-hr incubation with neutrophils.
(J) MFI values of membrane Her2/neu staining of
SKBR3 cells after 4-hr incubation with neutrophils
and the indicated conditions. Note the significant
loss of Her2/neu staining after SKBR3 cells are
opsonized with trastuzumab and incubated with
neutrophils and the even greater loss of Her2/neu
on trastuzumab-opsonized SKBR3 cells after in-
cubation of the neutrophils with an anti-SIRPa
antibody. Results shown are averages from 2 in-
dependent experiments with neutrophils from 5
individual donors. Statistical significance was
tested with ANOVA; **p % 0.01, *p% 0.05.
(K) Representative histogram of LIVE/DEAD-violet staining of SKBR3 cells, after opsonization with trastuzumab and 4-hr incubation with neutrophils and CD47-
SIRPa block by anti-SIRPa antibody. The gating strategy for living (LIVE/DEAD-violet) and dead (LIVE/DEAD-violet+) cells (left) is shown. Histograms for DiD
staining as a representation of the amount of membrane for the gated live and dead SKBR3 cells (right).
(L) Quantification of the percentage of membrane loss in living and dead SKBR3 cells after incubation with neutrophils for 4 hr, using the gating strategy as
explained in Figures 3B and 4K. Note that SKBR3 cells identified as dead by LIVE/DEAD staining lost the greatest amount of membrane compared to living
SKBR3 cells. The percentage of membrane loss was calculated as compared to control SKBR3 cells alone. The results shown are averages ± SEM of 3 in-
dependent experiments with neutrophils from 7 individual donors. Statistical significance was tested with ANOVA; **p% 0.01, *p % 0.05.with piceatannol, another inhibitor of Syk, thereby validating our
screen. Further validation of a number of drugs against targets
that had been implicated in neutrophil Fcg receptor signaling
(Hawkins et al., 2010; Mo´csai et al., 2010) revealed the involve-
ment of intracellular Ca2+, phosphoinositol-3 kinase (PI3K), and
the myosin light-chain kinase (MLCK) (Figures 7D–7L). This anal-3952 Cell Reports 23, 3946–3959, June 26, 2018ysis demonstrated that any inhibitor of antibody-induced trogo-
cytosis also suppressed neutrophil ADCC. In fact, until now, we
had not observed any condition that prevented neutrophil trogo-
cytosis that did not severely compromise killing. Clearly, these
findings support the idea that a trogocytic process is at the
base of neutrophil cytotoxicity toward cancer cells. The
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Figure 5. Neutrophil Trogoptosis Occurs
In Vivo
(A) Clearance of TA99-opsonized B16F10 mela-
noma cells in vivo after blocking CD47-SIRPa in-
teractions by SSL6. Mice were injected with
B16F10 melanoma cells treated or not treated
with SSL6 and labeled with DiI or DiD in a 1:1 ratio,
and metastatic tumor load in the liver was quan-
tified 3 days after injection of the melanoma cells.
Blocking of CD47-SIRPa interactions strongly in-
hibited themetastatic load of the tumor cells in the
liver.
(B) Representative overview of imaging field of
view in the mouse liver, showing TA99-opsonized
B16F10 melanoma cells (red) and neutrophils
(green). As shown in the insets, numerous neu-
trophils can be found carrying pieces of tumor cell
membrane inside (6 hr after the onset of the
experiment, 103 objective). See also Video S5.
(C) Quantification of the amount of neutrophils
positive for tumor cell membrane material (6 hr
after the onset of the experiment; results shown
are averages of 4 mice per group).
(D) Visual representation asmeasured by confocal
imaging in the mouse liver of the effect of in vivo
depletion of neutrophils by anti-Ly6G antibody.
B16F10 cells (blue); neutrophils (left, green). Effect
of in vivo depletion of neutrophils by anti-Ly6G
antibody on the tumor load. Mice were depleted
from neutrophils by injection of anti-Ly6G anti-
body 72 hr before and at the time of the start of the
experiment. At that time, mice were injected with
B16F10 melanoma cells, and metastatic tumor
load in the liver was quantified 3 days after injec-
tion of the melanoma cells (right). Results shown
are averages of 5–6 mice per group.
(E) Still images of intravital imaging in the liver of a
Lysm-egfp/SirpaDcyt mouse, taken from Video S6
6 hr after the onset of the experiment. TA99-
opsonized B16F10 melanoma cells were labeled
with DiI (red); neutrophils (green). As indicated by
the arrows, a neutrophil can be seen actively
trogocytosing a piece of membrane from the
antibody-opsonized tumor cell. Depletion of resi-
dent Kupffer cells using clodronate liposomes
to reduce phagocytosis of tumor cells by these
local macrophages permitted better visualization
of neutrophil trogocytosis. Scale bar represents
25 mm.
(F) Still images of intravital imaging in the liver of a
Lysm-egfp/SirpaDcyt mouse, taken from Video S7
6 hr after the onset of the experiment. Neutrophils
(green); TA99-opsonized B16F10 melanoma cells were labeled with DiD (blue). During the experiment, propidium iodide (PI, red) was present to detect necrotic
cells. As indicated by the arrow in the still images, neutrophil-associated trogoptotic cell death is seen as shown by PI staining of nuclear DNA. Scale bar
represents 25 mm.contribution of the different signaling components appeared
roughly similar, irrespective of the presence or absence of
CD47-SIRPa interactions.
DISCUSSION
Here, we describe a cellular effector mechanism by which neu-
trophils destroy antibody-opsonized cancer cells. It is interestingand perhaps also surprising to note that this cytotoxic mecha-
nism, which we have termed trogoptosis (for reasons further out-
lined below), is essentially mechanical in nature because it
causes disruption of the target cell plasma membrane, leading
to a necrotic (i.e., lytic) type of cancer cell destruction. Clearly,
this method of killing is different from other known mechanisms
of immune cell-mediated cytotoxicity, including the apoptotic
cell death that is induced by NK cells and CTLs and theCell Reports 23, 3946–3959, June 26, 2018 3953
before a?er
Neutrophil Her2/Neu
Her2/Neu
0.9%
2.1% 2.0%
16.5%
Her2/Neu
p
N tneita
p
O tneita
B
A Figure 6. Tumor-Infiltrated Neutrophils of
Patients with Breast Cancer Are Positive
for Her2/neu, and Evaluation of Biopsies
from Patients with Cancer Treated with
Therapeutic Antibodies Revealed Cancer
Membrane in Neutrophils
(A) Immunohistochemical analysis of biopsies of
patients with breast cancer stained for MPO to
detect neutrophils (blue) andHer2/neu (brown) of a
patient (patient M, see table in Figure S5C) with
Her2/neu+ breast cancer before and after neo-
adjuvant trastuzumab therapy.
(B) FACS analysis of breast cancer biopsies from a
patient with a Her2/neu+ tumor (patient N, see
table in Figure S5C) and from a patient with a Her2/
neu tumor (patient O, see table in Figure S5C).
Samples were enzymatically degraded, fixed, and
permeabilized; stained for CD14 and CD33 to
identify neutrophils; and stained for the presence
of Her2/neu.phagocytic cell death mediated by macrophages. In particular,
killing triggered by NK cells and CTLs, whether independent or
dependent of antibodies and Fcg receptor triggering, is well
known to depend on granule exocytosis-dependent mecha-
nisms (Bryceson and Long, 2008). By using cells from patients
with FHL-5 lacking the munc18-2/STXBP2 protein that is known
to form an absolute requirement for granule exocytosis in all leu-
kocytes, including NK cells and neutrophils (Zhao et al., 2013),
we were able to demonstrate that neutrophil ADCC is indepen-
dent of granule release. Similarly, the neutrophil NADPH oxidase
appeared dispensable for neutrophil ADCC, thereby showing
that neutrophil ADCC toward tumor cells does not depend on
the classic antimicrobial mechanisms. Furthermore, macro-
phages appear to use phagocytosis primarily for eliminating anti-
body-opsonized cancer cells (Chao et al., 2010a; G€ul et al.,
2014). It thus appears that trogoptosis is a mechanism of cancer
cell destruction that is restricted primarily to neutrophils.
It also is clear from our current findings, which are supported
by previous studies (van Spriel et al., 2001, 2003), that direct
effector-target cell interactions mediated by the CD11b/CD18
integrin play a pivotal role in neutrophil cytotoxicity. In particular,
CD11b/CD18 appears important for conjugate formation that in
turn was shown to form a prerequisite for trogocytosis and
killing. The fact that integrins, including the CD11b/CD18 integ-
rin, mediate high-affinity interactions with their ligands is consis-3954 Cell Reports 23, 3946–3959, June 26, 2018tent with the apparent mechanical nature
of the process, which we anticipate re-
quires pulling forces of a certain magni-
tude to be exerted by the neutrophil
upon the target cell plasma membrane.
Our findings with human neutrophils,
which also are supported by our in vivo
intravital microscopy studies in mice,
clearly fuel the idea that trogoptosis has
an intimate causal relation to the well-es-
tablished phenomenon of trogocytosis.
That there is at least a common causefor the two phenomena is not only supported by the observations
that they coincide in a spatio-temporal fashion (Figures 3 and 4;
Video S4) but also because of the identical underlying mecha-
nistic requirements, such as the integrin dependence and the
various intracellular signaling events downstream of the neutro-
phil Fc receptor required (e.g., Figure 7). Trogocytosis has been
described in the context of, for example, antigen presentation, in
which T lymphocytes acquire fragments of the antigen-present-
ing cell plasma membrane (Joly and Hudrisier, 2003; Martı´nez-
Martı´n et al., 2011; Ralston et al., 2014), but it was originally
described by Tabiasco et al. (2002) to occur during NK cell cyto-
toxicity. However, in NK cells, trogocytosis can clearly be disso-
ciated from the cytotoxic mechanism, which is rather granule
mediated (Figure S2C; Bryceson and Long, 2008), whereas NK
cell trogocytosis is not (Figure S3D). In fact, until now, trogocyto-
sis has been essentially a phenomenon without a direct purpose
in immune cell function. Notably, a study by Ralston et al. (2014)
provided convincing evidence that a trogocytic mechanism ex-
erted by the evolutionary distant parasite E. histolyticawas caus-
ally linked to the lytic tissue damage that occurs during infection
with the parasite. A more recent study provided evidence that
trogocytosis is mechanistically distinct from the process of
phagocytosis in the same organism (Somlata et al., 2017). Of in-
terest, another study also demonstrated trogocytosis of anti-
body-opsonized cancer cells, and although this was linked to
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Figure 7. Signaling Downstream of Fcg re-
ceptor Is Required for Neutrophil Trogocy-
tosis of Antibody-Opsonized Tumor Cells.
Neutrophil conjugate formation, trogocytosis,
and killing of cancer cells by trogoptosis requires
signaling downstream of Fcg receptor via the
tyrosine kinase Syk (A–C), intracellular Ca2+ (D–F),
phopshoinositol-3-kinase (PI3K) (G–I), and myosin
light chain kinase (MLCK) (J–L).
(A–C) First, the role of signaling downstream of
neutrophil Fcg receptor was revealed by the use of
an inhibitor of Syk (BAY61-3606; 10 mM) on con-
jugate formation (A), trogocytosis (B), and cyto-
toxicity (C). The other indicated target signaling
molecules were initially identified by screening the
LOPAC library of 1,260 pharmacologically active
compounds for inhibition of trogocytosis as
measured by flow cytometry (also see Table S1).
(D–L) Relevant targets were validated for
their effects of conjugate formation (D, G, and J),
trogocytosis (E, H, and K) and cytotoxicity (F, I,
and L) with the indicated inhibitors (at concentra-
tions of 10 mM 1,2-bis[2-aminophenoxy]ethane-
N,N,N0,N0-tetraacetic acid tetrakis[acetoxymethyl
ester] [BAPTA-AM]; 100 nM [Wortmannin]; 50 mM
[ML7]).
(M) Schematic representation of the Fcg receptor
signaling pathway with the signaling components
involved in trogocytosis and the respective in-
hibitors to show their involvement (gray). The
schematic representation shows a working model
for the way in which Fcg receptor signaling leads
to conjugate formation, neutrophil trogocytosis,
and, ultimately, to cancer cell death.
Data are averages ± SEMs from 3–6 indepen-
dent experiments that included 3–6 individual
donors; statistical significance was tested with
ANOVA followed by Sidak posthoc test; *p% 0.05,
**p% 0.01.
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cancer cell death in the long run (during a 48-hr period), no evi-
dence for a subsequent causally associated lytic mechanism
of killing was provided (Velmurugan et al., 2016). It is worth
emphasizing that, as opposed to the examples mentioned
involving T cells, NK cells, and parasites, neutrophil trogocytosis
is strictly dependent on the presence of antibodies directed
against the tumor cells. Thus, depending on the exact condi-
tions, trogoptosis appears to be a generic mechanism by which
neutrophils destroy antibody-opsonized cancer cells, which
includes both solid cancer cells, as shown herein, and hemato-
logic cancer cells, although the exact requirements for the latter
appear somewhat distinct (D.J.v.R. et al., unpublished data).
Moreover, our results indicate that the trogocytosis process in-
volves typical and well-defined signaling events downstream of
Fcg receptor in neutrophils, which include activities of the tyro-
sine kinase Syk, PI3K, and MLCK, as well as a role for intracel-
lular Ca2+. These events are anticipated to coordinate the cyto-
skeletal rearrangements and the actin-myosin contraction that
underlie neutrophil trogocytosis and trogoptotic cancer cell
death (Figure 7M). Finally, although we believe that both phe-
nomena (i.e., trogocytosis and trogoptosis) are essentially part
of the same coordinated mechanical process that is triggered
in neutrophils downstream of their Fc receptors during ADCC to-
ward cancer cells, it does not necessarily mean that the two pro-
cesses are synonymous in the sense that every single ‘‘bite’’ of
the neutrophil directly causes lethal membrane disruption in
the target cell. Our preliminary observations (H.L.M. et al., un-
published data) indicate the following: (1) it may be a proportion
of the trogocytic events that leads to definitive target cell lysis,
and (2) there clearly appears to be an effect of accumulation of
the trogocytosis-related membrane damage to target cell death
(Figures 4K and 4L), and we are investigating this relation more
carefully.
One intriguing aspect of the cell death triggered by trogoptosis
that we describe here is that it is essentially a lytic (i.e., necrotic)
process. This means that it may not only be important for the
direct destruction of antibody-opsonized cancer cells but also
it may cause the release of danger-associated molecular pat-
terns (DAMPs) and tumor (neo)antigens from the killed cancer
cells. This may be instrumental in the establishment of a sterile
inflammatory environment and the initiation of durable cytotoxic
T cell responses, which may be important for the generation of
an effective antitumor immune response (Ahrens et al., 2012;
Chen and Nun˜ez, 2010; Matzinger, 2002; Sancho et al., 2008).
What is interesting is that all of these processes may be sup-
ported positively by the targeting of CD47-SIRPa interactions,
including the following: (1) as we show here, the potentiation of
neutrophil trogoptosis, causing both direct killing and the release
of DAMPs; (2) the enhanced removal of tumor cells by macro-
phages (Chao et al., 2010b); and (3) by causing an enhanced
clearance and uptake of tumor material by antigen-presenting
cells, which leads to improved and more effective cytotoxic
T cell responses against tumors (DiLillo and Ravetch, 2015; Liu
et al., 2015; Soto-Pantoja et al., 2014; Tseng et al., 2013). In
line with this, it has been demonstrated that disruption of
CD47-SIRPa interactions between red cells and CD4+ dendritic
cells, respectively, also may contribute to the activation of the
dendritic cells, and this may further help to generate effective3956 Cell Reports 23, 3946–3959, June 26, 2018antitumor T cell immunity (van den Berg and van Bruggen,
2015; Yi et al., 2015).
One remaining question is whether neutrophil-mediated tro-
goptosis is relevant during other conditions (e.g., during viral
infection), and this may shed light on the physiological function
of neutrophil-induced trogoptosis. It is known that during infec-
tion with HIV or influenza virus, antibodies are generated that
can opsonize and eliminate virus-infected cells by ADCC (Nim-
merjahn et al., 2015). Neutrophils also can exert ADCC toward
those cells, and it is conceivable that neutrophils also do this
by trogoptosis. Finally, it is feasible that neutrophil trogoptosis
plays a role in the damage to host cells during various conditions
of antibody-mediated autoimmunity.
Collectively, the knowledge acquired here relating to themech-
anism of neutrophil-mediated antibody-dependent destruction of
cancer cells and itsmodulation by theCD47-SIRPa axis is likely to
create additional opportunities for optimizing the clinical efficacy
of antibody therapy in cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Cell Lines and Primary Cells
B In Vivo Mouse Studies
d METHOD DETAILS
B Generation of Genetically Modified Cells
B Isolation of Effector Cells
B Flow Cytometry experiments
B Respiratory burst and myeloperoxidase (MPO) pro-
duction during ADCC
B Immuno electron microscopy
B Scanning electron microscopy
B Conjugate formation assay
B Trogocytosis FACS assay
B Antibody-dependent cellular cytotoxicity (ADCC)
B Live cell imaging
B Intravital microscopy of the liver
B Staining of tumor samples from breast cancer patients
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Data analysis and statistics
d DATA AND SOFTWARE AVAILIBILITY
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, seven videos, and one table
and can be found with this article online at https://doi.org/10.1016/j.celrep.
2018.05.082.
ACKNOWLEDGMENTS
We are grateful to Dr. O¨zden Sanal (Hacettepe University, Ankara, Turkey) for
providing patient material; to Ben Morris, Erik Mul, Anton Tool, and Edith van
de Vijver for their help with the experiments and/or their analysis; and to Georg
Kraal, Søren Moestrup, Sjaak Neefjes, and Arnoud Sonnenberg for useful dis-
cussions and for critically reading the manuscript. We also gratefully
acknowledge the contribution of Joost Bakker from SciComVisuals for
graphics, including the Graphical Abstract. This research was funded in part
by the Dutch Cancer Society (grant no. 10300) and the Landsteiner Research
Foundation (grant no. 1223).
AUTHOR CONTRIBUTIONS
H.L.M., L.B., X.W.Z., M.v.H., D.J.v.R., L.W.T., K. Schornagel, P.V., K.F., H.J.,
P.H., C.L., R.L.B., and J.H.W.L. contributed to the design, execution, and eval-
uation of the data. J.J.B., I.K., J.v.d.W.T.B., K. Seeger, S.R., D.P., E.S., and
C.W.M.-v.d.H.v.O. provided the patient material. T.M. provided the SirpaDcyt
mice. R.v.B., D.R., R.A.W.v.L., T.W.K., P.K., and T.K.v.d.B. designed the ex-
periments and supervised the research. T.K.v.d.B. and H.L.M. wrote the
manuscript.
DECLARATION OF INTERESTS
T.K.v.d.B. is the inventor of patent EP2282772 entitled ‘‘Compositions and
Methods to Enhance the Immune System, which is owned by Stichting San-
quin Bloed Voorziening, relating to the targeting of CD47-SIRPa interactions
in the context of antibody therapy in cancer.
Received: November 17, 2017
Revised: March 30, 2018
Accepted: May 23, 2018
Published: June 26, 2018
SUPPORTING CITATIONS
The following references appear in the Supplemental Information: Tintinger
et al. (2005).
REFERENCES
Ahrens, S., Zelenay, S., Sancho, D., Hanc, P., Kjær, S., Feest, C., Fletcher, G.,
Durkin, C., Postigo, A., Skehel, M., et al. (2012). F-actin is an evolutionarily
conserved damage-associated molecular pattern recognized by DNGR-1, a
receptor for dead cells. Immunity 36, 635–645.
Albanesi, M., Mancardi, D.A., Jo¨nsson, F., Iannascoli, B., Fiette, L., Di Santo,
J.P., Lowell, C.A., and Bruhns, P. (2013). Neutrophils mediate antibody-
induced antitumor effects in mice. Blood 122, 3160–3164.
Barclay, A.N., and van den Berg, T.K. (2014). The Interaction Between Signal
Regulatory Protein Alpha (SIRPalpha) and CD47: Structure, Function, and
Therapeutic Target. Annu. Rev. Immunol. 32, 25–50.
Borregaard, N., Sørensen, O.E., and Theilgaard-Mo¨nch, K. (2007). Neutrophil
granules: a library of innate immunity proteins. Trends Immunol. 28, 340–345.
Bryceson, Y.T., and Long, E.O. (2008). Line of attack: NK cell specificity and
integration of signals. Curr. Opin. Immunol. 20, 344–352.
Calafat, J., Janssen, H., Sta˚hle-Ba¨ckdahl, M., Zuurbier, A.E., Knol, E.F., and
Egesten, A. (1997). Human monocytes and neutrophils store transforming
growth factor-alpha in a subpopulation of cytoplasmic granules. Blood 90,
1255–1266.
Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S.,
Jan, M., Cha, A.C., Chan, C.K., Tan, B.T., et al. (2010a). Anti-CD47 antibody
synergizes with rituximab to promote phagocytosis and eradicate non-Hodg-
kin lymphoma. Cell 142, 699–713.
Chao, M.P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A.A., Gentles,
A.J., Volkmer, J., Weiskopf, K., Willingham, S.B., Raveh, T., Park, C.Y., et al.
(2010b). Calreticulin is the dominant pro-phagocytic signal on multiple human
cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94.
Chen, G.Y., andNun˜ez, G. (2010). Sterile inflammation: sensing and reacting to
damage. Nat. Rev. Immunol. 10, 826–837.
de Saint Basile, G., Me´nasche´, G., and Fischer, A. (2010). Molecular mecha-
nisms of biogenesis and exocytosis of cytotoxic granules. Nat. Rev. Immunol.
10, 568–579.DiLillo, D.J., and Ravetch, J.V. (2015). Differential Fc-Receptor Engagement
Drives an Anti-tumor Vaccinal Effect. Cell 161, 1035–1045.
Dustin, M.L., and Long, E.O. (2010). Cytotoxic immunological synapses. Im-
munol. Rev. 235, 24–34.
Eruslanov, E.B., Bhojnagarwala, P.S., Quatromoni, J.G., Stephen, T.L., Ran-
ganathan, A., Deshpande, C., Akimova, T., Vachani, A., Litzky, L., Hancock,
W.W., et al. (2014). Tumor-associated neutrophils stimulate T cell responses
in early-stage human lung cancer. J. Clin. Invest. 124, 5466–5480.
Fevre, C., Bestebroer, J., Mebius, M.M., de Haas, C.J., van Strijp, J.A., Fitzger-
ald, J.R., and Haas, P.J. (2014). Staphylococcus aureus proteins SSL6 and
SElX interact with neutrophil receptors as identified using secretome phage
display. Cell. Microbiol. 16, 1646–1665.
Glennie, M.J., and van de Winkel, J.G. (2003). Renaissance of cancer thera-
peutic antibodies. Drug Discov. Today 8, 503–510.
G€ul, N., Babes, L., Siegmund, K., Korthouwer, R., Bo¨gels, M., Braster, R., Vi-
darsson, G., ten Hagen, T.L., Kubes, P., and van Egmond, M. (2014). Macro-
phages eliminate circulating tumor cells after monoclonal antibody therapy.
J. Clin. Invest. 124, 812–823.
Hawkins, P.T., Stephens, L.R., Suire, S., and Wilson, M. (2010). PI3K signaling
in neutrophils. Curr. Top. Microbiol. Immunol. 346, 183–202.
Hernandez-Ilizaliturri, F.J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman,
A., Repasky, E., and Czuczman, M.S. (2003). Neutrophils contribute to the bio-
logical antitumor activity of rituximab in a non-Hodgkin’s lymphoma severe
combined immunodeficiency mouse model. Clin. Cancer Res. 9, 5866–5873.
Herrero-Turrio´n, M.J., Calafat, J., Janssen, H., Fukuda, M., and Mollinedo, F.
(2008). Rab27a regulates exocytosis of tertiary and specific granules in human
neutrophils. J. Immunol. 181, 3793–3803.
Inagaki, K., Yamao, T., Noguchi, T., Matozaki, T., Fukunaga, K., Takada, T.,
Hosooka, T., Akira, S., and Kasuga, M. (2000). SHPS-1 regulates integrin-
mediated cytoskeletal reorganization and cell motility. EMBO J. 19, 6721–
6731.
Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R.,
Traver, D., van Rooijen, N., and Weissman, I.L. (2009). CD47 is upregulated
on circulating hematopoietic stem cells and leukemia cells to avoid phagocy-
tosis. Cell 138, 271–285.
Joly, E., and Hudrisier, D. (2003). What is trogocytosis and what is its purpose?
Nat. Immunol. 4, 815.
Kuijpers, K.C., Kuijpers, T.W., Zeijlemaker, W.P., Lucas, C.J., van Lier, R.A.,
and Miedema, F. (1990). Analysis of the role of leukocyte function-associated
antigen-1 in activation of human influenza virus-specific T cell clones.
J. Immunol. 144, 3281–3287.
Kuijpers, T.W., Tool, A.T., van der Schoot, C.E., Ginsel, L.A., Onderwater, J.J.,
Roos, D., and Verhoeven, A.J. (1991). Membrane surface antigen expression
on neutrophils: a reappraisal of the use of surface markers for neutrophil acti-
vation. Blood 78, 1105–1111.
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W.A., Xu, H., Peng, H., Fu,
Y.X., and Xu, M.M. (2015). CD47 blockade triggers T cell-mediated destruction
of immunogenic tumors. Nat. Med. 21, 1209–1215.
Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D.,
Jr., van Rooijen, N., and Weissman, I.L. (2009). CD47 is an adverse prognostic
factor and therapeutic antibody target on human acute myeloid leukemia stem
cells. Cell 138, 286–299.
Martı´nez-Martı´n, N., Ferna´ndez-Arenas, E., Cemerski, S., Delgado, P., Turner,
M., Heuser, J., Irvine, D.J., Huang, B., Bustelo, X.R., Shaw, A., and Alarco´n, B.
(2011). T cell receptor internalization from the immunological synapse is medi-
ated by TC21 and RhoG GTPase-dependent phagocytosis. Immunity 35,
208–222.
Matzinger, P. (2002). The danger model: a renewed sense of self. Science 296,
301–305.
Meeths, M., Entesarian, M., Al-Herz, W., Chiang, S.C., Wood, S.M., Al-Ateeqi,
W., Almazan, F., Boelens, J.J., Hasle, H., Ifversen, M., et al. (2010). Spectrum
of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5
patients with mutations in STXBP2. Blood 116, 2635–2643.Cell Reports 23, 3946–3959, June 26, 2018 3957
Mo´csai, A., Ruland, J., and Tybulewicz, V.L. (2010). The SYK tyrosine kinase: a
crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387–402.
Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N., and
Bousso, P. (2013). The mechanism of anti-CD20-mediated B cell depletion re-
vealed by intravital imaging. J. Clin. Invest. 123, 5098–5103.
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G.,
Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008). Immunoglob-
ulin G fragment C receptor polymorphisms and clinical efficacy of trastuzu-
mab-based therapy in patients with HER-2/neu-positive metastatic breast
cancer. J. Clin. Oncol. 26, 1789–1796.
Nimmerjahn, F., and Ravetch, J.V. (2008). Fcgamma receptors as regulators of
immune responses. Nat. Rev. Immunol. 8, 34–47.
Nimmerjahn, F., Gordan, S., and Lux, A. (2015). FcgR dependent mechanisms
of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol.
36, 325–336.
Oldham, R.K., and Dillman, R.O. (2008). Monoclonal antibodies in cancer ther-
apy: 25 years of progress. J. Clin. Oncol. 26, 1774–1777.
Ralston, K.S., Solga, M.D., Mackey-Lawrence, N.M., Somlata, Bhattacharya,
A., and Petri, W.A., Jr. (2014). Trogocytosis by Entamoeba histolytica contrib-
utes to cell killing and tissue invasion. Nature 508, 526–530.
Reeves, E.P., Lu, H., Jacobs, H.L., Messina, C.G., Bolsover, S., Gabella, G.,
Potma, E.O., Warley, A., Roes, J., and Segal, A.W. (2002). Killing activity of
neutrophils is mediated through activation of proteases by K+ flux. Nature
416, 291–297.
Ring, N.G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J.P.,
George, B.M., Lietzenmayer, M., McKenna, K.M., Naik, T.J., McCarty, A.,
et al. (2017). Anti-SIRPa antibody immunotherapy enhances neutrophil and
macrophage antitumor activity. Proc. Natl. Acad. Sci. USA 114, E10578–
E10585.
Roos, D., van Bruggen, R., andMeischl, C. (2003). Oxidative killing of microbes
by neutrophils. Microbes Infect. 5, 1307–1315.
Rosseau, S., Selhorst, J., Wiechmann, K., Leissner, K., Maus, U., Mayer, K.,
Grimminger, F., Seeger, W., and Lohmeyer, J. (2000). Monocyte migration
through the alveolar epithelial barrier: adhesion molecule mechanisms and
impact of chemokines. J. Immunol. 164, 427–435.
Sancho, D., Mour~ao-Sa´, D., Joffre, O.P., Schulz, O., Rogers, N.C., Pennington,
D.J., Carlyle, J.R., and Reis e Sousa, C. (2008). Tumor therapy in mice via an-
tigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118,
2098–2110.
Segal, A.W. (2005). How neutrophils kill microbes. Annu. Rev. Immunol. 23,
197–223.
Siders, W.M., Shields, J., Garron, C., Hu, Y., Boutin, P., Shankara, S., Weber,
W., Roberts, B., and Kaplan, J.M. (2010). Involvement of neutrophils and nat-
ural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor
models. Leuk. Lymphoma 51, 1293–1304.
Somlata, N.-T., Nakada-Tsukui, K., and Nozaki, T. (2017). AGC family kinase 1
participates in trogocytosis but not in phagocytosis in Entamoeba histolytica.
Nat. Commun. 8, 101.
Soto-Pantoja, D.R., Miller, T.W., Frazier, W.A., and Roberts, D.D. (2012). Inhib-
itory signaling through signal regulatory protein-a is not sufficient to explain the
antitumor activities of CD47 antibodies. Proc. Natl. Acad. Sci. USA 109,
E2842–E2845, author reply E2844–E2845.
Soto-Pantoja, D.R., Terabe, M., Ghosh, A., Ridnour, L.A., DeGraff, W.G., Wink,
D.A., Berzofsky, J.A., and Roberts, D.D. (2014). CD47 in the tumor microenvi-
ronment limits cooperation between antitumor T-cell immunity and radio-
therapy. Cancer Res. 74, 6771–6783.
Strome, S.E., Sausville, E.A., and Mann, D. (2007). A mechanistic perspective
of monoclonal antibodies in cancer therapy beyond target-related effects.
Oncologist 12, 1084–1095.
Suzuki, E., Kataoka, T.R., Hirata, M., Kawaguchi, K., Nishie, M., Haga, H., and
Toi, M. (2015). Trogocytosis-mediated expression of HER2 on immune cells
may be associated with a pathological complete response to trastuzumab-3958 Cell Reports 23, 3946–3959, June 26, 2018based primary systemic therapy in HER2-overexpressing breast cancer pa-
tients. BMC Cancer 15, 39.
Tabiasco, J., Espinosa, E., Hudrisier, D., Joly, E., Fournie´, J.J., and Vercellone,
A. (2002). Active trans-synaptic capture of membrane fragments by natural
killer cells. Eur. J. Immunol. 32, 1502–1508.
Taylor, R.P., and Lindorfer, M.A. (2015). Fcg-receptor-mediated trogocytosis
impacts mAb-based therapies: historical precedence and recent develop-
ments. Blood 125, 762–766.
Tintinger, G., Steel, H.C., and Anderson, R. (2005). Taming the neutrophil: cal-
cium clearance and influx mechanisms as novel targets for pharmacological
control. Clin. Exp. Immunol. 141, 191–200.
Topalian, S.L., Drake, C.G., and Pardoll, D.M. (2015). Immune checkpoint
blockade: a common denominator approach to cancer therapy. Cancer Cell
27, 450–461.
Treffers, L.W., Zhao, X.W., van der Heijden, J., Nagelkerke, S.Q., van Rees,
D.J., Gonzalez, P., Geissler, J., Verkuijlen, P., van Houdt, M., de Boer, M.,
et al. (2018). Genetic variation of human neutrophil Fcg receptors and SIRPa
in antibody-dependent cellular cytotoxicity towards cancer cells. Eur. J. Immu-
nol. 48, 344–354.
Tseng, D., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., Fathman,
J.W., Fernhoff, N.B., Seita, J., Inlay, M.A., Weiskopf, K., Miyanishi, M., and
Weissman, I.L. (2013). Anti-CD47 antibody-mediated phagocytosis of cancer
by macrophages primes an effective antitumor T-cell response. Proc. Natl.
Acad. Sci. USA 110, 11103–11108.
Valgardsdottir, R., Cattaneo, I., Klein, C., Introna, M., Figliuzzi, M., and Golay,
J. (2017). Human neutrophils mediate trogocytosis rather than phagocytosis of
CLL B cells opsonized with anti-CD20 antibodies. Blood 129, 2636–2644.
van Beek, E.M., Zarate, J.A., van Bruggen, R., Schornagel, K., Tool, A.T., Ma-
tozaki, T., Kraal, G., Roos, D., and van den Berg, T.K. (2012). SIRPa controls
the activity of the phagocyte NADPH oxidase by restricting the expression of
gp91(phox). Cell Rep. 2, 748–755.
van Egmond, M., and Bakema, J.E. (2013). Neutrophils as effector cells for
antibody-based immunotherapy of cancer. Semin. Cancer Biol. 23, 190–199.
van de Vijver, E., Maddalena, A., Sanal, O¨., Holland, S.M., Uzel, G., Madkaikar,
M., de Boer, M., van Leeuwen, K., Ko¨ker, M.Y., Parvaneh, N., et al. (2012).
Hematologically important mutations: leukocyte adhesion deficiency (first up-
date). Blood Cells Mol. Dis. 48, 53–61.
van den Berg, T.K., and van Bruggen, R. (2015). Loss of CD47 makes dendritic
cells see red. Immunity 43, 622–624.
van Spriel, A.B., Leusen, J.H., van Egmond, M., Dijkman, H.B., Assmann, K.J.,
Mayadas, T.N., and van deWinkel, J.G. (2001). Mac-1 (CD11b/CD18) is essen-
tial for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse
formation. Blood 97, 2478–2486.
van Spriel, A.B., van Ojik, H.H., Bakker, A., Jansen, M.J., and van de Winkel,
J.G. (2003). Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated
immunity to melanoma. Blood 101, 253–258.
Velmurugan, R., Challa, D.K., Ram, S., Ober, R.J., and Ward, E.S. (2016).
Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized
Tumor Cells. Mol. Cancer Ther. 15, 1879–1889.
Weiskopf, K., Ring, A.M., Ho, C.C., Volkmer, J.P., Levin, A.M., Volkmer, A.K.,
Ozkan, E., Fernhoff, N.B., van de Rijn, M., Weissman, I.L., and Garcia, K.C.
(2013). Engineered SIRPa variants as immunotherapeutic adjuvants to anti-
cancer antibodies. Science 341, 88–91.
Yi, T., Li, J., Chen, H., Wu, J., An, J., Xu, Y., Hu, Y., Lowell, C.A., and Cyster,
J.G. (2015). Splenic Dendritic Cells Survey Red Blood Cells for Missing Self-
CD47 to Trigger Adaptive Immune Responses. Immunity 43, 764–775.
Zhao, X.W., van Beek, E.M., Schornagel, K., van der Maaden, H., van Houdt,
M., Otten, M.A., Finetti, P., van Egmond, M., Matozaki, T., Kraal, G., et al.
(2011). CD47-signal regulatory protein-a (SIRPa) interactions form a barrier
for antibody-mediated tumor cell destruction. Proc. Natl. Acad. Sci. USA
108, 18342–18347.
Zhao, X.W., Kuijpers, T.W., and van den Berg, T.K. (2012a). Is targeting of
CD47-SIRPa enough for treating hematopoietic malignancy? Blood 119,
4333–4334, author reply 4334–4335.
Zhao, X.W., Matlung, H.L., Kuijpers, T.W., and van den Berg, T.K. (2012b). On
the mechanism of CD47 targeting in cancer. Proc. Natl. Acad. Sci. USA 109,
E2843, author reply E2844–E2845.
Zhao, X.W., Gazendam, R.P., Drewniak, A., van Houdt, M., Tool, A.T., van
Hamme, J.L., Kustiawan, I., Meijer, A.B., Janssen, H., Russell, D.G., et al.(2013). Defects in neutrophil granulemobilization and bactericidal activity in fa-
milial hemophagocytic lymphohistiocytosis type 5 (FHL-5) syndrome caused
by STXBP2/Munc18-2 mutations. Blood 122, 109–111.
Zhu, E.F., Gai, S.A., Opel, C.F., Kwan, B.H., Surana, R., Mihm, M.C., Kauke,
M.J., Moynihan, K.D., Angelini, A., Williams, R.T., et al. (2015). Synergistic
innate and adaptive immune response to combination immunotherapy with
anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell
27, 489–501.Cell Reports 23, 3946–3959, June 26, 2018 3959
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-CD11b, clone 44A ATCC Cat# ATCC HB-249; RRID:CVCL_J601
Anti-CD18, clone IB4 ATCC Cat# ATCC HB-10164; RRID: CVCL_0339
CLB-LFA1/2 Sanquin Cat# M1385 P35
Anti-CD11c Rosseau et al., 2000 N/A
Monovalent human Fc fragments Bethyl Cat# A80-104AP; RRID: AB_67062
Anti-CD32 F(ab’)2, clone 7.3 Ancell Cat# 181-520
Anti-CD16 F(ab’)2, clone 3G8 Ancell Cat# 165-520
Anti-CD47 F(ab’)2, clone B6H12 Zhao et al., 2011 N/A
Anti-SIRPa, clone 12C4 Zhao et al., 2011 N/A
Anti-MPO Herrero-Turrio´n et al., 2008 N/A
Anti-Lactoferrin Herrero-Turrio´n et al., 2008 N/A
Anti-CD33-PE, clone WM53 BD Biosciences Cat# 555450; RRID: AB_395843
Anti-CD14-PE-Cy7, clone M5E2 Biolegend Cat# 301813; RRID: AB_389352
Anti-CD340-APC, clone 24D2 Biolegend Cat# 324407; RRID: AB_756123
Anti-HER2, clone 4B5 Roche Cat# 790-2991; RRID: AB_2335975
Anti-GR1, clone 1A8 BioXcell Cat# BE0075-1; RRID: AB_1107721
Trastuzumab Roche N/A
Cetuximab Merck KGaA N/A
TA99 BioXcell Cat# BE0151; RRID: AB_10949462
Chemicals, Peptides, and Recombinant Proteins
Anti-APC MACS beads Miltenyi Cat# 130-090-855; RRID: AB_244367
Anti-CD56 MACS beads Miltenyi Cat# 130-050-401
Liberase TM Roche Cat# 000000005401119001
Intraprep kit Beckman Coulter Cat# A07803
G-CSF Neupogen N/A
IFNg PEPROTECH Cat# 300-02
LIVE/DEAD viability kit ThermoFisher Cat# L34955
Lipophilic membrane dyes (DiO, DiD) Invitrogen Cat# V22886, V22887
Library of Pharmacologically Active Compounds (LOPAC) Sigma-Aldrich Cat# LO4100
TO-PRO-3 iodide Invitrogen Cat# T3605
Calcein-AM green / red-orange Invitrogen Cat# C34852, C34851
Syk inhibitor: BAY 61-3606 Sigma Cat# B9685-5MG
PI3K inhibitor: Wortmannin Sigma Cat# 12-338
MLCK inhibitor: ML7 Sigma Cat# I2764-5MG
Critical Commercial Assays
Amplex Red assay Molecular Probes Cat# A22188
MPO ELISA Hycult Cat# HK324-02; RRID: AB_10989641
Experimental Models: Cell Lines
Human: SKBR3 ATCC Cat# HTB-30; RRID:CVCL_0033
Human: A431 ATCC Cat# CRL-1555; RRID:CVCL_0037
Mouse: B16F10 ATCC Cat# CRL-6475; RRID:CVCL_0159
Human: HEK293T ATCC Cat#: ATCC CRL-3216; RRID: CVCL_0063
(Continued on next page)
e1 Cell Reports 23, 3946–3959.e1–e6, June 26, 2018
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Organisms/Strains
Mice: Lysm-egfp Dr. T. Graf N/A
Mice: Lysm-egfp/SIRPaDcyt Inagaki et. al., 2000 N/A
Oligonucleotides
shRNA targeting sequence: CD47: 50CCGGGCACAA-
TTACTTGGACTAGTTCTCGAGAACTAGTCCAAG
TAATTGTGCTTTTT-30
Zhao et al., 2011 N/A
Software and Algorithms
Prism 7 Graphpad N/A
FloJo v10 Tree Star N/A
ImageJ NIH N/A
Volocity Perkin-Elmer N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Timo van
den Berg (t.k.vandenberg@sanquin.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and Primary Cells
The Her2/neu-positive human breast cancer cell line SKBR3 (source: female) was routinely cultured in IMDMmedium supplemented
with 20% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37C and 5% CO2. The hu-
man epidermoid carcinoma cell line A431 (source: female) was routinely cultured in RPMI 1640medium supplemented with 10% (v/v)
fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37C and 5% CO2. Primary neutrophils or
NK cells, isolated from healthy donors or from Familial Hemophagocytic Lymphoadenocytosis type 5 (FHL5) patients, Chronic Gran-
ulomatous Disease (CGD) patients, LAD-I patients and LAD-III patients were used (see Figure S1E for patient details). Blood was
collected after informed consent and according to the Declaration of Helsinki 1964. Studies on human blood samples were approved
by the Sanquin Research institutional medical ethical committee. After isolation (see Methods section below for a detailed protocol),
neutrophils were cultured for either 4 hr or overnight in RPMI 1640 culture medium, supplemented with 10% (v/v) fetal bovine serum,
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, in the presence of 10 ng/ml clinical grade recombinant G-CSF
and 50 ng/ml recombinant human interferon-g at a concentration of 5x106 cells/ml. The use of unstimulated neutrophils in trogocy-
tosis and ADCC assays lead to similar results, although the overall response was in general lower (data not shown). NK cells were
cultured overnight in RPMI 1640 culture medium, supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 1% (v/v) L-glutamine, at a concentration of 5x106 cells/ml.
Mouse neutrophils fromC57BL/6Jmice were isolated according to isolation protocol described below. After isolation, mouse neu-
trophils were cultured overnight in RPMI 1640 culture medium, supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 1% (v/v) L-glutamine, in the presence of 10 ng/ml clinical grade recombinant G-CSF and 50 ng/ml recombinant
murine interferon-g at a concentration of 5x106 cells/ml.
In Vivo Mouse Studies
Male and female 8-12 weeks old Lysm-egfp knockin reporter mice (Dr. T. Graf, Albert Einstein College, New York) and Lysm-egfp/
SirpaDcytmice(Inagaki et al., 2000) were housed at 20-25C, 50%–60% humidity with a 12/12 light/dark cycle in the Animal Health
Unit at The University of Calgary (Calgary, Canada), and all procedures were approved by The University of Calgary Institutional
Animal Care and Use Committee. For all in vivo imaging studies, after tumors were injected, mice were randomly assigned to exper-
imental groups.
METHOD DETAILS
Generation of Genetically Modified Cells
CD47 was knocked down in SKBR3 cells with shRNA (50CCGGGCACAA-TTACTTGGACTAGTTCTCGAGAACTAGTCCAAG
TAATTGTGCTTTTT-30; referred to as SKBR3 CD47KD cells), resulting in 10%–15% expression of normal CD47 surface levels asCell Reports 23, 3946–3959.e1–e6, June 26, 2018 e2
shown previously.(Zhao et al., 2011) Knock-down of CD47 was routinely verified by flow cytometry and was found to be stable over
periods upto 6 months in culture (see Figure S4G). SKBR3 cells expressing empty vector shRNA were used as control. For overex-
pression of lamin B-GFP in SKBR3 cells, the coding sequence of full-length lamin B1 was cloned into the lentiviral vector pRRL PPT
SFFVGFP prester SIN. Lentiviral particles were produced in HEK293T cells whichwere transient cotransfected with the lentiviral vec-
tor, pMDLgp, RSVrev and pCMV-VSVg. On day 2 and 3 after transfection, virus containing supernatant was harvested and directly
added to WT SKBR3 cells after filtering through a 0,45 mM filter. GFP-positive cells were selected by flow cytometry sorting before
their use on further assays.
For overexpression of mouse CD47, the coding sequence of mouse CD47 was cloned into pENTR-d-TOPO; this construct was
recombined with pLenti6.3/V5-DEST by LRClonase II (Invitrogen) to obtain pLenti6.3-mCD47. SKBR3 CD47KD cells were lentivirally
transducedwith pLenti6.3-mCD47, as described for theCD47 knockdown construct(Zhao et al., 2011), followed by positive selection
with blasticidin. A431 cells expressing human Her2/Neu were generated by retroviral transduction, followed by positive selection us-
ing puromycin.
Isolation of Effector Cells
Neutrophils (PMNs) were isolated as previously described.(Kuijpers et al., 1991) Briefly, granulocytes were isolated by density
gradient centrifugation with isotonic Percoll and erythrocyte lysis. NK cells were isolated from the PBMC fraction of blood after Per-
coll fractionation by means of anti-CD56-coated MACS beads, according to procedures provided by the manufacturer. Mouse neu-
trophils from C57BL/6J mice were isolated with anti-GR1 antibody coupled to APC (clone 1A8, concentration 1:200) and anti-APC
MACS beads, according to the procedures provided by the manufacturer.
Flow Cytometry experiments
In FACS analysis of tumor samples from breast cancer patients (see Figures S5C and S5D) neutrophils were identified by positive
staining for CD33 and negative staining for CD14. In these samples, Her2/neu was stained by use of anti-CD340 antibody. Briefly,
solid tumor samples were minced and enzymatically degraded into single cell suspensions by incubating at 37C in HEPES disso-
ciation buffer containing Liberase TM (Roche, 125 mg/ml) for 1 hr. Single cell suspensions were washed in HEPES buffer, fixed and
permeabilized using intraprep kit (Beckman Coulter) according to protocol provided by the manufacturer, and stained with the
mentioned antibodies, after which the cells were measured on a LSRII flow cytometer (BD Biosciences).
Respiratory burst and myeloperoxidase (MPO) production during ADCC
NADPH oxidase activity was evaluated during ADCC by measuring extracellular hydrogen peroxide release in an Amplex Red assay
(Molecular Probes) as previously described.(van Beek et al., 2012) Samples were measured in the presence of Amplex Red (0.5 mM)
and horseradish peroxidase (1 U/ml). Fluorescence was measured on a plate reader (TECAN) and maximal slope was determined
over a 2-minute interval to calculate NADPH oxidase activity. MPO release from PMNs during ADCC of cancer cells was measured
by ELISA (Hycult), according to protocol of the manufacturer.
Immuno electron microscopy
Conjugate formation and trogocytosis of PMNs and tumor cells were visualized by electron microscopy. Briefly, 1x106/ml SKBR3
cells were labeled with biotin (concentration 0.01 mg/ml, EZ Link Sulfo NHS Biotin, ThermoFisher) by incubation in HEPES- buffer
at 37C for 30 min. Thereafter, 10 3 106 human neutrophils were coincubated with 2 3 106 target cells (E:T ratio = 5:1) in the
absence or presence of 10 mg/ml trastuzumab (Roche) for the indicated times at 37C in a 5% CO2 atmosphere to allow conjugate
formation to occur. Cells were fixed in 2% paraformaldehyde + 0.2% glutaraldehyde in 0.1 M PHEM buffer (60 mM PIPES, 25 mM
HEPES, 2 mM MgCl2, 10 mM EGTA, pH 6.9) and then processed for ultrathin cryosectioning as previously described.(Calafat
et al., 1997) Briefly, 60-nm cryosections were cut at 120C with diamond knives in a cryoultramicrotome (Leica Aktiengesell-
schaft, Vienna, Austria) and transferred with a mixture of sucrose and methylcellulose onto formvarcoated copper grids. The grids
were placed on 35-mm Petri dishes containing 2% (w/v) gelatine. Ultrathin frozen sections were incubated at room temperature
with polyclonal antibodies either against MPO (1/14,000) or lactoferrin (1/1,200) followed by 10-nm protein A-conjugated colloidal
gold (EM Lab, Utrecht University, Netherlands) as first marker. To block protein A binding sites the sections were fixed for 10 min.
with 1% (w/v) glutaraldehyde, then a polyclonal antibody against biotin (1/20,000) incubation, marked by 15- nm protein A-con-
jugated colloidal gold (EM Lab, Utrecht University, Netherlands). After immuno labeling, the sections were embedded in a mixture
of methylcellulose and uranyl acetate and examined with a Philips CM10 electron microscope (FEI company, Eindhoven, the
Netherlands).
Scanning electron microscopy
SKBR3 cells were cultured on glass coverslips (13 mm). PMNs were added in E:T ratio 5:1 for 45 min in the presence of 5 mg/ml Tras-
tuzumab. Cells were fixed with McDowells Trumps Fixative. Water was removed from the samples with increasing concentrations
ethanol and dried in a desiccator. Samples were examined with a Phenom scanning electron microscope (FEI company, Eindhoven,
the Netherlands).e3 Cell Reports 23, 3946–3959.e1–e6, June 26, 2018
Conjugate formation assay
A total of 1x106 G-CSF/IFNg-primed human neutrophil effector cells labeled with CellTrace calcein violet-AM fluorescent dye (Invi-
trogen, Grand Island, NY, USA) were incubated with 2 3 105 SKBR3 cells stained with CMTPX/cell-tracker red fluorescent dye (In-
vitrogen) (E:T ratio = 5:1) in the absence or presence of 5 mg/ml Trastuzumab for 30min at 37C in 5%CO2.. After incubation, the cells
were fixed with 1.2% (w/v) paraformaldehyde in PBS. Samples were run in an ImageStreamX flow cytometer (Amnis Corporation,
Seattle, WA, USA) and images were acquired for 10,000 events/sample. Cell images of double-positive events CMTPX+/Calcein+
were analyzed to visualize and quantify effector-target cell conjugate formation with the Amnis’ IDEAS data analysis package.
Trogocytosis FACS assay
The transfer of membrane from tumor cell to neutrophil was quantified by flow cytometry. Membranes of tumor target cells were
labeled with lipophilic membrane dye (DiO, 5 mM, Invitrogen; DiI, 5 mM, Invitrogen) for 30 min at 37C. After washing with PBS, cells
were incubated together with neutrophils in a U-bottom 96-well plate at a E:T ratio of 5:1 or in the absence or presence of 5 mg/ml
trastuzumab (Roche) or 2 mg/ml cetuximab (Merck KGaA). Samples were fixed with stopbuffer containing 0.5% (w/v) PFA, 1% (w/v)
BSA and 20mM NaF at several time points between 0 and 120 min and measured on a FACS. After gating for the neutrophil popu-
lation, based on SSC and a nuclear marker (stable lamin B-GFP expression) in the target cells (see also Figure 3B), the mean
fluorescent intensity (MFI) and the percentage of cells positive for DiO/DiD were evaluated. For measuring both trogocytosis and
ADCC at the same time by flow cytometry, lamin-GFP expressing SKBR3 target cells were labeled with a lipophilic membrane
dye (DiD), a cytoplasmic dye (calcein red-orange) and incubated with neutrophils for 4 hr in the absence or presence of 5mg/ml tras-
tuzumab. After the incubation period, cells were washed and stained for dead cells by use of a LIVE/DEAD viability kit (ThermoFisher).
Afterward, samples were washed and fixed with stopbuffer containing 0.5% (w/v) PFA, 1% (w/v) BSA and 20mMNaF and measured
on FACS.
Controls and CD47-SIRPa interference in trogocytosis assay
Control experiments were carried out where target cells had been labeled with either biotin, or where trastuzumab itself was labeled
with a fluorescent label by the use of Lightning Link Conjugation kit (Innova Biosciences) (see Figure S4H). Alternatively, the plasma
membrane had been genetically labeled by transfection of the target cells with a GFP-CAAX construct, which expresses an N-ter-
minal GFP-tagged tetra-amino acidmotif (CAAX), localizing GFP to the plasmamembrane. These experiments showed similar results
compared to labeling the target cell with lipophilic membrane dye. In indicated experiments, CD47-SIRPa interactions were inhibited,
either by use of anti-CD47 F(ab’)2, anti-SIRPa antibody, or by knockdown of CD47 in target cells, as stated in the legends of the
Figures.
Compound Screening in Trogocytosis assay
To further evaluate the mechanistic pathway involved in trogocytosis, we made use of our FACS-based trogocytosis assay as
described above, in combination with the Library of Pharmacologically Active Compounds (LOPAC, Sigma-Aldrich), consisting of
1280 compounds with described pharmacological actions, including kinase inhibitors, receptor ligands, and approved drugs. All
compounds in this library were used in a concentration of 10 mM. As controls on each 96-well plate, SKBR3 cells and SKBR3
CD47KD cells were incubated together with PMNs either in the absence or presence of trastuzumab. The normalization method
used was Normalized Percent Inhibition. The LOPAC library was screened with three biological replicates and was further analyzed
both by MFI and by percentage positive PMNs. Hits were defined as over 80% inhibition of membrane transfer from tumor cells to
PMNs as measured by FACS.
Hits found by use of the LOPAC library were validated on conjugate formation assay, trogocytosis assay and ADCC assay, and
included inhibitors of Syk kinase (BAY 61-3606), myosin light chain kinase (ML7) and PI3K (Wortmannin).
Antibody-dependent cellular cytotoxicity (ADCC)
Target cells were labeled with 100 mCi 51Cr (Perkin-Elmer) for 90 min at 37C. After 3 washes with PBS, in indicated experiments,
CD47-SIRPa interactions were blocked by incubating SKBR3 cells or SKBR3 CD47KD msCD47KI cells (1x106) with 10 mg of
SSL6 (kind gift from J.A. van Strijp and P.J.A. Haas, Utrecht, the Netherlands) for 30 min on ice. After 2 washes with PBS, 5x103 cells
were incubated in RPMI culture medium supplemented with 10% (v/v) FCS for 4 hr at 37C and 5% CO2 in a 96-well U-bottom plate
together with PMNs in a E:T ratio of 50:1 in the presence of the appropriate antibodies. After the incubation of target cells and effector
cells, supernatant was harvested and analyzed for radioactivity in a gamma counter (Wallac). The percentage of cytotoxicity was
calculated as [(experimental cpm- spontaneous cpm)/ (total cpm- spontaneous cpm)] x 100%. All conditions were measured in trip-
licate. To visualize target cells after ADCC assay, effector cells were incubated with target cells for 4 hr at 37C (T:E ratio 1:5 for NK
cells; T:E ratio 1:50 for PMNs), after which cytospins were made of 30,000- 60,000 total cells in a cytocentrifuge (Cytospin 4,
Shandon).
For integrin blocking experiments mAbs 44A and IB4 against CD11b/CD18 were pre-incubated either separately or together
with PMNs at 10 mg/ml each for 10 min, after which the cells were used in ADCC, trogocytosis and conjugate formation experiments.
Other integrins were blocked with CLB-LFA1/2 (Sanquin, the Netherlands), anti-CD11a(Kuijpers et al., 1990), CBR-p150/4G1 (AbD
Serotec) and anti-CD11c(Rosseau et al., 2000), which were also used at 10 mg/ml in a similar fashion. For blocking Fcg receptors, aCell Reports 23, 3946–3959.e1–e6, June 26, 2018 e4
combination of monovalent human Fc fragments to block FcgRI (CD64), mAb 7.3 against FcgRII (CD32), and mAb 3G8 against
FcgRIII (CD16) were pre-incubated with PMNs for 20 min at a concentration of 10 mg/ml, after which cells were used in conjugate
formation and ADCC experiments. An appropriate isotype control (Ancell) was used as control condition.
Live cell imaging
Target cells were cultured on glass coverslips (25 mm or 30 mm diameter) and labeled with DiO (Invitrogen, concentration 5 mM) to
label the membrane. Calcein-AM green or -red-orange (concentration 10 mM, Invitrogen) was used to label the cytoplasm of the
target cells. In some experiments, as stated in the Figure legends, TO-PRO-3 iodide (1 mM concentration, Invitrogen) was present
in the culture medium during imaging. Target cells were incubated with PMNs in E:T ratio 5:1 for periods up to 4 hr at 37C and
5% CO2 in IMDM culture medium supplemented with 20% (v/v) FCS. Imaging was started within 5 min after initiation of the exper-
iment and was performed at various indicated times and intervals either in a LSM 510 META laser scanning microscope (Carl Zeiss)
microscope, or in a Leica TCM sp8 confocal microscope (Leica).
Intravital microscopy of the liver
Experimental B16F10 liver model
Lysm-egfp knockin reporter mice (Dr. T. Graf, Albert Einstein College, New York) and Lysm-egfp/SirpaDcytmice(Inagaki et al., 2000)
were used for visualization of hepatic neutrophils.
Animals were anesthetized by intraperitoneal injection of a mixture of 200 mg/kg ketamine (Bayer Animal Health) and 10 mg/kg
Xylazine (Bimeda-MTC). The right jugular vein was cannulated to administer additional anesthesia and propidium iodide to visualize
necrotic cells (Sigma-Aldrich). Surgical preparation of the liver and intrasplenic injection of tumor cells was done as briefly described
in the following. Laparotomy along the linea alba was performed followed by removal of the skin and abdominal muscle along the
costal margin to the mid axillary line to expose the liver. Melanoma (B16F10) cells (2x105) were labeled with fluorescent DiI or DiD
membrane dye (Sigma-Aldrich) and injected into the spleen. Mice were splenectomised shortly after injection of the B16F10 cells.
Therapeutic antibody (TA99, BioXell, 200 mg) was injected intraperitoneal 2 h prior to intravital microscopy. To deplete Kupffer cells,
mice were injected with 200 mL clodronate liposomes (0.69mol/L) intraveneousely 48 h prior to the start of the experiment. For deple-
tion of neutrophils, mice were injected twice with anti-Ly6G antibody (clone 1A8) 72 h prior and at the start of the experiment. For
blocking CD47-SIRPa interactions, B16F10 melanoma cells (1x106) were incubated with 10 mg of SSL6 (kind gift from J.A. van Strijp
and P.J.A. Haas) and intrasplenically injected after repeated washing.
Intravital microscopy of B16F10 liver model
Spinning-disk multichannel-fluorescence intravital microscopy of mouse liver was performed with an Olympus IX81 inverted micro-
scope, equipped with an Olympus focus drive and a motorized stage (Applied Scientific Instrumentation, Eugene, OR, USA) and
fitted with a motorized objective turret equipped with 4X/0.16 UPLANSAPO, 10X/0.40 UPLANSAPO and 20X/0.70 UPLANSAPO
objective lenses and coupled to a confocal light path (WaveFx; Quorum Technologies, Guelph, ON, Canada) based on a modified
Yokogawa CSU-10 head (Yokogawa Electric Corporation, Tokyo, Japan). The mice were placed on the right lateral position and
the liver was exteriorized on a heated microscope stage. All exposed tissues were moistened with saline-soaked gauze to prevent
dehydration during image acquisition. For all experiments body temperature was maintained and the liver continuously superfused
with physiological saline buffer. Volocity software (Perkin Elmer) was used for image acquisition.
Staining of tumor samples from breast cancer patients
Breast tumor samples from a female Her2/Neu- positive patient (see Figure S5C for patient characteristics) were embedded in
paraffin, cut into 4-mm sections and further processed as previously described(Suzuki et al., 2015). Briefly, tissue sections were de-
paraffinized and rehydrated, and endogenous peroxidase activity was quenched with 3% hydrogen peroxide. Furthermore, sections
were blocked with 5% (v/v) normal goat serum (Abcam), and incubated with anti-MPO and anti-HER2 (Ready to use, clone 4B5, rab-
bit monoclonal, Roche). Appropriate secondary antibodies were applied for 1 hr, after which sections were stained withMACH2 dou-
ble stain 2 (Biocare Medical). In accordance with the Declaration of Helsinki, informed consent was obtained from all breast cancer
patients.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data analysis and statistics
Flow cytometry data were analyzed by Flowjo software (Tree Star, Inc, Ashland, OR, USA). Image analysis of the intravital B16F10
tumor model imaging was done with Volocity (Perkin Elmer) and ImageJ (NIH).
Where appropriate, figure legends define n and the dispersion and precision measures. Data are expressed as mean ± 1 SEM,
unless otherwise specified. For each experiment, unless otherwise noted, n represents the number of individual biological replicates.
Statistical differences between two groups were tested in Prism (Graphpad) by t test; multiple comparisons were tested by One-way
ANOVA-test followed by Sidak post hoc test for correction of multiple comparison. In the overall analysis of the LOPAC librarye5 Cell Reports 23, 3946–3959.e1–e6, June 26, 2018
screening, for each compound the distribution of the experimental values for replicates, readouts and CD47 condition (wild-type
versus knockdown) was compared with the distribution of the negative controls in the Wilcoxon-test. The resulting p values were
corrected for multiple testing by the Benjamin Hochberg method.
DATA AND SOFTWARE AVAILIBILITY
Hits found by use of the LOPAC library are presented in Table S1.Cell Reports 23, 3946–3959.e1–e6, June 26, 2018 e6
